

Purified anti-mouse CD4 Antibody

Catalog# / Size	100401 / 50 µg 100402 / 500 µg
Clone	GK1.5
Regulatory Status	RUO
Other Names	L3T4, T4
Isotype	Rat IgG2b, κ
Description	CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, Ick.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse CTL clone V4
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - Quality tested IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Additional reported applications (for the relevant formats) include: blocking of CD4 ⁺ T cell activation ^{1,4,11} , thymocyte costimulation ³ , <i>in vitro</i> and <i>in vivo</i> depletion ^{2,5-8} , blocking of egg-sperm cell adhesion ^{1,4} , immunohistochemical staining of acetone-fixed frozen sections ^{9,10} , immunoprecipitation ^{1,2} , and spatial biology (IBEX) ^{12,13} . The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Application References	<ol style="list-style-type: none"> Dialynas DP, <i>et al.</i> 1983. <i>J. Immunol.</i> 131:2445. (Block, IP) Dialynas DP, <i>et al.</i> 1983. <i>Immunol. Rev.</i> 74:29. (IP, Deplete) Wu L, <i>et al.</i> 1991. <i>J. Exp. Med.</i> 174:1617. (Costim) Godfrey DI, <i>et al.</i> 1994. <i>J. Immunol.</i> 152:4783. (Block) Gavett SH, <i>et al.</i> 1994. <i>Am. J. Respir. Cell. Mol. Biol.</i> 10:587. (Deplete) Schuyler M, <i>et al.</i> 1994. <i>Am. J. Respir. Crit. Care Med.</i> 149:1286. (Deplete) Ghobrial RR, <i>et al.</i> 1989. <i>Clin. Immunol. Immunopathol.</i> 52:486. (Deplete) Israelski DM, <i>et al.</i> 1989. <i>J. Immunol.</i> 142:954. (Deplete) Zheng B, <i>et al.</i> 1996. <i>J. Exp. Med.</i> 184:1083. (IHC) Frei K, <i>et al.</i> 1997. <i>J. Exp. Med.</i> 185:2177. (IHC) Felix NJ, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:388. (Block) Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

1. Zhang S, *et al.* 2017. Nature. 10.1038/nature24283. [PubMed](#)
2. Chami B, *et al.* 2017. Sci Rep. 7:10181. [PubMed](#)
3. Tsukumo S, *et al.* 2006. J Immunol. 177:8365. [PubMed](#)
4. Kobayashi A, *et al.* 2021. Front Immunol. 12:650856. [PubMed](#)
5. Liao X, *et al.* 2022. Front Immunol. 12:768813. [PubMed](#)
6. Paterson MJ, *et al.* 2020. PLoS Pathog. 16:e1008733. [PubMed](#)
7. Hummel JF, *et al.* 2020. Mucosal Immunol. 0.720138889. [PubMed](#)
8. Smith CJ, *et al.* 2018. J Immunol. 200:1580. [PubMed](#)
9. Mazor R, *et al.* 2018. Proc Natl Acad Sci U S A. 115:E733. [PubMed](#)
10. Krovi SH, *et al.* 2019. Proc Natl Acad Sci U S A. 116:22252. [PubMed](#)
11. Thelin MA, *et al.* 2017. Diabetes. 66:2220. [PubMed](#)
12. Thi VAD, *et al.* 2019. Mol Cells. 42:869. [PubMed](#)
13. Burrello C, *et al.* 2018. Front Med (Lausanne). 5:21. [PubMed](#)
14. Shirakawa K, *et al.* 2017. PLoS One. 12:e0186303. [PubMed](#)
15. Landuyt AE, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. [PubMed](#)
16. Fernandes V, *et al.* 2020. PLoS Pathog. 16:e1008464. [PubMed](#)
17. Bajiña S, *et al.* 2021. Front Immunol. 11:577718. [PubMed](#)
18. Murata A, *et al.* 2020. Front Immunol. 11:775. [PubMed](#)
19. Wan Mohd Zawawi WFA, *et al.* 2021. Sci Rep. 11:10278. [PubMed](#)
20. Rieck M, *et al.* 2017. Eur J Immunol. 47:677. [PubMed](#)
21. Duvvuri M, *et al.* 2019. Biomater Sci. 7:1863. [PubMed](#)
22. Yang J, *et al.* 2020. Front Immunol. 10:3048. [PubMed](#)
23. Prado C, *et al.* 2021. J Neuroinflammation. 18:292. [PubMed](#)
24. Carpenter SM, *et al.* 2017. PLoS Pathog. 13:e1006704. [PubMed](#)
25. Gao J, *et al.* 2017. Oncol Lett. 14:2954. [PubMed](#)
26. Hashimoto K, *et al.* 2021. J Dermatol Sci. 102:177. [PubMed](#)
27. Haque M, *et al.* 2021. Viruses. 13:. [PubMed](#)
28. Mayer JU, *et al.* 2020. Front Immunol. 11:592325. [PubMed](#)
29. Tian K, *et al.* 2021. J Immunol Res. 2021:6297332. [PubMed](#)
30. Hirano J, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. [PubMed](#)
31. Draganov D, *et al.* 2021. NPJ Breast Cancer. 7:22. [PubMed](#)
32. Rossi DC, *et al.* 2021. J Clin Invest. 131:. [PubMed](#)
33. Wabitsch S, *et al.* 2021. STAR Protoc. 2:100517. [PubMed](#)
34. Schafflick D, *et al.* 2020. Nat Commun. 247:11. [PubMed](#)
35. Xie MM, *et al.* 2017. Eur J Immunol. 47:1136. [PubMed](#)
36. Zhou AC, *et al.* 2017. Front Immunol. 1.136111111. [PubMed](#)
37. Niss Arfelt K, *et al.* 2017. Blood. 129:866. [PubMed](#)
38. Stefanescu C, *et al.* 2021. Front Oncol. 11:765151. [PubMed](#)
39. Mostafavi H, *et al.* 2022. PLoS Pathog. 18:e1010185. [PubMed](#)
40. Tan L, *et al.* 2017. Int J Nanomedicine. 12:3095. [PubMed](#)
41. McLeod RL, *et al.* 2018. Oncotarget. 9:34459. [PubMed](#)
42. Jackson JW, *et al.* 2021. Mol Ther Oncolytics. 22:444. [PubMed](#)
43. Mayer KA, *et al.* 2021. FASEB J. 35:e21217. [PubMed](#)
44. Lasrado N, *et al.* 2021. Microorganisms. 9:. [PubMed](#)
45. Shimokawa C *et al.* 2017. Immunity. 46(5):863-874 . [PubMed](#)
46. Sun H, *et al.* 2018. J Cell Biol. 217:1453. [PubMed](#)
47. Chen S, *et al.* 2018. Immunohorizons. 0.345138889. [PubMed](#)
48. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. [PubMed](#)
49. Wang N, *et al.* 2021. Mol Ther Oncolytics. 20:71. [PubMed](#)
50. Skeate JG, *et al.* 2018. PLoS One. 13:e0191311. [PubMed](#)
51. Seelige R, *et al.* 2018. Sci Rep. 8:13670. [PubMed](#)
52. Yang SH, *et al.* 2017. Front Immunol. 8:1192. [PubMed](#)
53. Zhao L, *et al.* 2018. Nat Med. 24:1536. [PubMed](#)
54. Stacey MA, *et al.* 2017. J Clin Invest. 127:1463. [PubMed](#)
55. Sharma M, *et al.* 2020. Nat Commun. 11:661. [PubMed](#)
56. Ma W, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-15661-6. [PubMed](#)
57. Overacre-Delgoffe AE, *et al.* 2017. Cell. 169:1130. [PubMed](#)
58. Elsayed H, *et al.* 2018. J Virol. 92:e00428. [PubMed](#)
59. Gartlan KH, *et al.* 2019. Blood Adv. 2.110416667. [PubMed](#)
60. Hu M, *et al.* 2008. J Immunol. 180:6593. [PubMed](#)
61. Xie D, *et al.* 2020. Eur J Immunol. 50:1729. [PubMed](#)
62. Shokirova H, *et al.* 2021. Sci Rep. 11:8647. [PubMed](#)
63. Zareie P, *et al.* 2017. J Neuroinflammation. 0.630555556. [PubMed](#)
64. Leal AS, *et al.* 2019. Sci Rep. 5.286111111. [PubMed](#)
65. Hoves S, *et al.* 2018. J Exp Med. 215:859. [PubMed](#)
66. Hsiao CC, *et al.* 2021. Cells. 10:. [PubMed](#)
67. Horiuchi S, *et al.* 2021. Sci Immunol. :eabm3131. [PubMed](#)
68. Kinoshita H, *et al.* 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. [PubMed](#)
69. Pierini A, *et al.* 2017. JCI Insight. 2. [PubMed](#)
70. Sprouse ML, *et al.* 2018. JCI Insight. 3:e97322. [PubMed](#)
71. Lee JY, *et al.* 2018. Front Immunol. 0.678472222. [PubMed](#)
72. Liu M, *et al.* 2018. Diabetologia. 61:2333. [PubMed](#)
73. Sharabi A, *et al.* 2019. JCI Insight. 4:e126294. [PubMed](#)
74. Majer O, *et al.* 2019. Nature. 575:366. [PubMed](#)
75. Tao H, *et al.* 2021. Front Immunol. 12:623280. [PubMed](#)
76. Zelazowska MA, *et al.* 2020. Life Sci Alliance. :3. [PubMed](#)
77. Matsuo K, *et al.* 2018. J Invest Dermatol. 138:1764. [PubMed](#)
78. Sandler M, *et al.* 2020. Gastroenterology. 158:253. [PubMed](#)
79. Yates K, *et al.* 2018. Proc Natl Acad Sci U S A. 115:2162. [PubMed](#)
80. Zhang H, *et al.* 2017. J Immunol. 198:2133. [PubMed](#)

81. Simula L *et al.* 2018. Cell reports. 25(11):3059-3073 . [PubMed](#)
82. Biton M *et al.* 2018. Cell. 175(5):1307-1320 . [PubMed](#)
83. Zander R, *et al.* 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. [PubMed](#)
84. De Ponte Conti B, *et al.* 2021. Elife. 10:. [PubMed](#)
85. Chen HW, *et al.* 2021. Biomedicines. 9:. [PubMed](#)
86. Ikezoe T, *et al.* 2021. Biomolecules. 11:. [PubMed](#)
87. Shiozawa S, *et al.* 2022. iScience. 25:103537. [PubMed](#)
88. Goh W, *et al.* 2020. Cell Rep. 33:108285. [PubMed](#)
89. Chen X, *et al.* 2019. Methods Mol Biol. 2048:131. [PubMed](#)
90. Rosenbaum M, *et al.* 2019. Nat Commun. 2.05. [PubMed](#)
91. Meyers JL, *et al.* 2018. PLoS One. 13:e0207007. [PubMed](#)
92. Floudas A, *et al.* 2017. J Immunol. 199:707. [PubMed](#)
93. Zhang YN, *et al.* 2021. Sci Adv. 7:eabj3107. [PubMed](#)
94. Pradhan P, *et al.* 2017. JCI Insight. 2. [PubMed](#)
95. Song K, *et al.* 2017. Oncotarget. 8:38554. [PubMed](#)
96. Akiel M, *et al.* 2017. Cancer Res. 77:4014. [PubMed](#)
97. Duncan CG, *et al.* 2018. G3 (Bethesda). 0.892361111. [PubMed](#)
98. Wilhelmson AS, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:1519. [PubMed](#)
99. Roussey JA, *et al.* 2017. J Immunol. 199:3535. [PubMed](#)
100. Stefanski HE, *et al.* 2018. PLoS One. 13:e0198871. [PubMed](#)
101. Scortegagna M, *et al.* 2020. Nat Commun. 11:99. [PubMed](#)
102. Brownlie D, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
103. Tsai MS, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
104. Zhang Z, *et al.* 2020. Front Immunol. 1.844444444. [PubMed](#)
105. Rosenberg J, *et al.* 2020. Cell Systems. 10(5):433-444. [PubMed](#)
106. Scutts SR, *et al.* 2018. Cell Rep. 25:1953. [PubMed](#)
107. Liu J, *et al.* 2022. Stem Cell Res Ther. 13:247. [PubMed](#)
108. Lin Z, *et al.* 2021. Stem Cells. 39:240. [PubMed](#)
109. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. [PubMed](#)
110. Luu M, *et al.* 2019. Nat Commun. 10:760. [PubMed](#)
111. Di Dalmazi G, *et al.* 2019. J Immunol. 202:1350. [PubMed](#)
112. Dey P, *et al.* 2020. Cancer Discov. 10:608. [PubMed](#)
113. Mohrin M, *et al.* 2021. Aging Cell. 20:e13313. [PubMed](#)
114. Fujimura N, *et al.* 2016. J Vasc Surg. 64: 46-54. [PubMed](#)
115. Englezou PC, *et al.* 2018. Mol Ther Nucleic Acids. 12:118. [PubMed](#)
116. Cole C, *et al.* 2018. Nucleic Acids Res. 46:e62. [PubMed](#)
117. Tang-Huau TL, *et al.* 2021. Viruses. 13: . [PubMed](#)
118. Zhang J, *et al.* 2019. Onco Targets Ther. 12:4985. [PubMed](#)
119. Zhang N, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. [PubMed](#)
120. Whittle JR, *et al.* 2020. Clin Cancer Res. 26:4120. [PubMed](#)
121. Liu H, *et al.* 2022. Animal Model Exp Med. 5:72. [PubMed](#)
122. Krämer TJ, *et al.* 2019. J Neuroinflammation. 16:163. [PubMed](#)
123. Shao Y, *et al.* 2017. Onco Targets Ther. 10:2675. [PubMed](#)
124. He X, *et al.* 2017. Cancer Biol Ther. 0.815277778. [PubMed](#)
125. Kästele V, *et al.* 2021. Mucosal Immunol. 14:717. [PubMed](#)
126. Prabakaran T, *et al.* 2021. EBioMedicine. 66:103314. [PubMed](#)
127. Sutiwisesak R, *et al.* 2020. PLoS Pathog. 16:e1009000. [PubMed](#)

RRID AB_312686 (BioLegend Cat. No. 100401)
 AB_312687 (BioLegend Cat. No. 100402)

Antigen Details

Structure	Ig superfamily, 55 kD
Distribution	Majority of thymocytes, T cell subset
Function	TCR co-receptor, T cell activation
Ligand/Receptor	MHC class II molecule
Cell Type	Dendritic cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Bierer BE, <i>et al.</i> 1989. <i>Annu. Rev. Immunol.</i> 7:579. 3. Janeway CA. 1992. <i>Annu. Rev. Immunol.</i> 10:645.
Gene ID	12504


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD4, Biotin anti-mouse CD4, FITC anti-mouse CD4, PE anti-mouse CD4, PE/Cyanine5 anti-mouse CD4, Purified anti-mouse CD4, PE/Cyanine7 anti-mouse CD4, APC/Cyanine7 anti-mouse CD4, Alexa Fluor® 647 anti-mouse CD4, Alexa Fluor® 488 anti-mouse CD4, Pacific Blue™ anti-mouse CD4, Alexa Fluor® 700 anti-mouse CD4, PerCP anti-mouse CD4, PerCP/Cyanine5.5 anti-mouse CD4, Brilliant Violet 421™ anti-mouse CD4, Ultra-LEAF™ Purified anti-mouse CD4, Alexa Fluor® 594 anti-mouse CD4, Brilliant Violet 711™ anti-mouse CD4, Brilliant Violet 510™ anti-mouse CD4, Brilliant Violet 605™ anti-mouse CD4, Brilliant Violet 785™ anti-mouse CD4, PE/Dazzle™ 594 anti-mouse CD4, APC/Fire™ 750 anti-mouse CD4, GoInVivo™ Purified anti-mouse CD4, Brilliant Violet 750™ anti-mouse CD4, Brilliant Violet 650™ anti-mouse CD4, Spark Blue™ 550 anti-mouse CD4, Spark NIR™ 685 anti-mouse CD4, KIRAVIA Blue 520™ anti-mouse CD4, PE/Fire™ 640 anti-mouse CD4, APC/Fire™ 810 anti-mouse CD4, PE/Fire™ 700 anti-mouse CD4, Spark Violet™ 538 anti-mouse CD4, Spark YG™ 593 anti-mouse CD4, Spark Blue™ 574 anti-mouse CD4 Antibody, Spark UV™ 387 anti-mouse CD4

Product Data



BALB/c mouse splenocytes were stained with purified CD4 (clone GK1.5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587